Monte Rosa signs $50M upfront Roche collaboration for MGDs; MRT-2359 shows early efficacy

Monte Rosa Therapeutics, Inc.

Upfront payment of $50M from Roche; potential milestones >$2B for initial oncology/neurology targets.
Roche gains exclusive license after pre-clinical; Monte Rosa leads discovery on initial targets.
MRT-2359 interim data: ~60% GSPT1 reduction in tumors; 2 partial responses in biomarker-positive patients.
Safety profile supports further development; Grade 4 AEs at 2mg were transient, no discontinuations.
Monte Rosa retains full ownership of pipeline; joint research committee governs collaboration.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Monte Rosa Therapeutics, Inc. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. valued at upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston (effective 2023-10-16).

Action: entry
Agreement: collaboration
Counterparty: F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.
Value: upfront payment of $50 million, and potential pre-clinical, clinical, commercial, and sales mileston
Effective: 2023-10-16

Exact text from the filing

On October 16, 2023, Monte Rosa Therapeutics AG (“Monte Rosa AG,” hereinafter the “Company”), a wholly-owned subsidiary of Monte Rosa Therapeutics, Inc., F. Hoffmann-La Roche Ltd (“Roche Basel”) and Hoffmann-La Roche Inc. (“Roche US” and together with Roche Basel, “Roche”) entered into a Collaboration and License Agreement (the “Agreement”).

View on SEC.gov

Browse all material agreements →

Monte Rosa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-053653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.